Infection · adults with renal vasculitis
Mycophenolate mofetil showed no clear difference in infection compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Death · adults with renal vasculitis
Intravenous immunoglobulin showed no clear difference in death compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Dialysis at one year · adults with renal vasculitis
The intervention may leads to lower dialysis at one year (low certainty).
1 finding from 1 review
Kidney function · adults with renal vasculitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dialysis · adults with renal vasculitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Response at 3 months · adults with renal vasculitis
Intravenous immunoglobulin may leads to higher response at 3 months compared with placebo (low certainty).
1 finding from 1 review
Relapse at 3 months · adults with renal vasculitis
Intravenous immunoglobulin showed no clear difference in relapse at 3 months compared with placebo (low certainty).
1 finding from 1 review
Adverse events · adults with renal vasculitis
Intravenous immunoglobulin may leads to higher adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious infection · adults with renal vasculitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death (all causes) · adults with renal vasculitis for maintenance therapy
Azathioprine showed no clear difference in death (median compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Kidney function · adults with renal vasculitis for maintenance therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dialysis · adults with renal vasculitis for maintenance therapy
Azathioprine showed no clear difference in dialysis (median compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Relapse · adults with renal vasculitis for maintenance therapy
Azathioprine showed no clear difference in relapse at 18 months compared with cyclophosphamide (moderate certainty).
2 findings from 1 review
Intervention not reported
Sustained remission · adults with renal vasculitis
The intervention may leads to higher sustained remission (low certainty).
1 finding from 1 review
Serious adverse events · adults with renal vasculitis for maintenance therapy
Azathioprine showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Infections · adults with renal vasculitis for maintenance therapy
Azathioprine showed no clear difference in infections compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Death · adults with renal vasculitis for maintenance therapy
Azathioprine may leads to lower death compared with methotrexate (low certainty).
1 finding from 1 review
Kidney function · adults with renal vasculitis for maintenance therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dialysis · adults with renal vasculitis for maintenance therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse · adults with renal vasculitis for maintenance therapy
Azathioprine showed no clear difference in relapse compared with methotrexate (low certainty).
1 finding from 1 review